Updated Jul 16, 2026
Saik Andrew has filed 3 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $218K.
Andrew Saik is the Chief Financial Officer at Arvinas, Inc., a biotechnology company focused on developing therapies for cancer and other diseases through its proprietary PROTAC technology. He has a background in finance and has held various roles in financial management within the biotech industry.
| Role | Chief Financial Officer |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-24 | ARVN | ARVINAS, INC. | S — Open-market sale | 5.7K | $8.16 | $46K |
| 2026-05-13 | ARVN | ARVINAS, INC. | S — Open-market sale | 11.1K | $9.94 | $111K |
| 2026-03-03 | ARVN | ARVINAS, INC. | A — Grant or award | 45.0K | $0.00 | |
| 2026-02-18 | ARVN | ARVINAS, INC. | S — Open-market sale | 5.1K | $11.89 | $61K |
Andrew Saik is the Chief Financial Officer at Arvinas, Inc., a biotechnology company focused on developing therapies for cancer and other diseases through its proprietary PROTAC technology. He has a background in finance and has held various roles in financial management within the biotech industry.…
3 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($218K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Saik Andrew profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.